放射性核素治疗
医学
医学物理学
临床试验
剂量学
放射治疗
核医学
电离辐射
放射科
病理
辐照
物理
核物理学
作者
Hanna Piwowarska-Bilska,Sara Kurkowska,Bożena Birkenfeld
出处
期刊:Cancers
[MDPI AG]
日期:2022-07-14
卷期号:14 (14): 3418-3418
被引量:10
标识
DOI:10.3390/cancers14143418
摘要
The article presents the problems of clinical implementation of personalized radioisotope therapy. The use of radioactive drugs in the treatment of malignant and benign diseases is rapidly expanding. Currently, in the majority of nuclear medicine departments worldwide, patients receive standard activities of therapeutic radiopharmaceuticals. Intensively conducted clinical trials constantly provide more evidence of a close relationship between the dose of radiopharmaceutical absorbed in pathological tissues and the therapeutic effect of radioisotope therapy. Due to the lack of individual internal dosimetry (based on the quantitative analysis of a series of diagnostic images) before or during the treatment, only a small fraction of patients receives optimal radioactivity. The vast majority of patients receive too-low doses of ionizing radiation to the target tissues. This conservative approach provides "radiation safety" to healthy tissues, but also delivers lower radiopharmaceutical activity to the neoplastic tissue, resulting in a low level of response and a higher relapse rate. The article presents information on the currently used radionuclides in individual radioisotope therapies and on radionuclides newly introduced to the therapeutic market. It discusses the causes of difficulties with the implementation of individualized radioisotope therapies as well as possible changes in the current clinical situation.
科研通智能强力驱动
Strongly Powered by AbleSci AI